The JAK inhibitor upadacitinib (Rinvoq) outperformed placebo in ankylosing spondylitis patients whose disease hadn't responded to standard biologic drug therapy, phase III trial data showed. Almost ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback